NCT07095465

Phase 3, Open Label Extension Study of ACP-204 in Lewy Body Dementia Psychosis

52-Week, Phase 3, Open-Label Extension Study of ACP-204 in Adults With Lewy Body Dementia Psychosis (LBDP)

• Status: Enrolling By Invitation
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 126 (estimated)
• Sponsor: ACADIA Pharmaceuticals Inc. · Industry
• Sex: All
• Age: 55 Years – 84 Years
• Healthy volunteers: Not accepted

Summary

A 52-Week, Phase 3, Open-Label Extension Study of ACP-204 in Adults With Lewy Body Dementia Psychosis (LBDP)

Conditions

• Lewy Body Dementia Psychosis

Interventions

Type	Name	Description
DRUG	ACP-204	Provided as 1 capsule, to be taken orally once daily

Timeline

• Start date: 2025-11-14
• Primary completion: 2029-02-01
• Completion: 2029-03-01
• First posted: 2025-07-31
• Last updated: 2026-03-24

Locations

11 sites across 1 country: United States

Regulatory

• FDA-regulated drug study